Mechanistically, we find that TR35 exerts anti-tumor effects by activating p-JNK/MAPK signaling and suppressing STAT3 signaling (including its downstream molecules such as c-Myc and Bcl-XL). The gene discussed is BCL2L1; the disease is neoplasm.